Roche is acquiring U.S.-Israeli biotech company 89bio, in a deal valued at up to $3.5 billion. Founded in 2018 and originating from Teva’s pipeline, 89bio develops treatments for advanced liver disease and metabolic disorders, especially its lead candidate pegozafermin, an FGF21 analogue in late-stage trials for metabolic dysfunction-associated steatohepatitis. The deal includes $14.50 per share in cash plus contingent value rights of up to $6 per share based on future milestones. Roche aims to leverage this acquisition to strengthen its presence in areas overlapping obesity, liver, and metabolic disease, amid growing competitive pressure in weight-loss and related therapies.
Read the full article on Calcalistech